Protagonist Therapeutics Inc (PTGX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $143.00 (-0.49%), Market cap $6.66B, 52-week low–high $43.77 ~ $105.98.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development c
Financial statements, price targets, institutional (13F) holdings and related news for Protagonist Therapeutics Inc are updated in real time on BlackAll Trade.
Protagonist Therapeutics Inc trades at $143.00 (-0.49%). Real-time quotes and charts are available on BlackAll Trade.
Protagonist Therapeutics Inc has a market cap of about $6.66B.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of ad